As BG Medicine Submits Cardio Risk Test to FDA, Some Pharmas See Opportunity for Preventive Therapy
January 11, 2012
As BG Medicine Submits Cardio Risk Test to FDA, Some Pharmas See Opportunity for Preventive Therapy
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- BG Medicine Says Data from 6,600-Patient Clinical Study Validates CardioScore Cardiac Risk Test
February 17, 2012 / ProteoMonitor - BG Medicine Partners with Framingham Study to Track Heart Attack Risk
May 1, 2009 / Genome Technology - BG Medicine Q1 Revenues Fall but Galectin-3 Sales Jump as Company Pursues Expanded Use for Test
May 17, 2012 / ProteoMonitor - Biodesix Inks Deal to Test Veristrat in Phase III Clinical Trial for Kadmon Lung Cancer Drug
March 2, 2012 / ProteoMonitor - Columbia Team IDs Two Protein Markers to Improve Prediction of Acute Kidney Injury, Adverse Effects
January 13, 2012 / ProteoMonitor